Back to Report Store Home

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

  • Published: Jun-2016
  • Report Code: GBIHC397MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 5

2.1 Significant Unmet Needs in Diabetic Complications Market 5

2.2 High Proportion of First-in-Class Innovation Offers Promise in Diabetic Complications 5

2.3 Deal Activity Varies with First-in-Class Status 5

3 The Case for Innovation 6

3.1 Growing Opportunities for Biologic Products 7

3.2 Diversification of Molecular Targets 7

3.3 Innovative First-in-Class Product Development Remains Attractive 7

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8

3.5 Sustained Innovation 8

3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 10

4.1 Diabetes Mellitus Overview 10

4.2 Diabetic Neuropathies 11

4.2.1 Disease Overview 11

4.2.2 Signs and Symptoms 11

4.2.3 Epidemiology and Etiology 12

4.2.4 Pathophysiology 12

4.2.5 Diagnosis and Staging 12

4.2.6 Prognosis 13

4.2.7 Treatment Options 13

4.3 Diabetic Nephropathy 14

4.3.1 Disease Overview 14

4.3.2 Sign and Symptoms 14

4.3.3 Epidemiology and Etiology 14

4.3.4 Pathophysiology 14

4.3.5 Diagnosis and Staging 14

4.3.6 Prognosis 15

4.3.7 Treatment Options 15

4.4 Diabetic Retinopathies 16

4.4.1 Disease Overview 16

4.4.2 Signs and Symptoms 16

4.4.3 Epidemiology and Etiology 16

4.4.4 Pathophysiology 16

4.4.5 Diagnosis and Staging 17

4.4.6 Prognosis 17

4.4.7 Treatment Options 17

4.5 Overview of Marketed Products in Diabetic Complications 18

4.5.1 Overview of Marketed Products in Diabetic Neuropathies 18

4.5.2 Overview of Marketed Products in Diabetic Nephropathy 20

4.5.3 Overview of Marketed Products in Diabetic Retinopathies 20

5 Assessment of Pipeline Product Innovation 22

5.1 Diabetic Neuropathies by Molecule Type, Phase and Therapeutic Target 22

5.1.1 Comparative Distribution of Programs between Diabetic Neuropathy Market and Pipeline by Therapeutic Target Family 24

5.1.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 25

5.2 Diabetic Nephropathy by Molecule Type, Phase and Therapeutic Target 27

5.2.1 Comparative Distribution of Programs between the Diabetic Nephropathy Market and Pipeline by Therapeutic Target Family 29

5.2.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 30

5.3 Diabetic Retinopathies by Molecule Type, Phase and Therapeutic Target 32

5.3.1 Comparative Distribution of Programs between the Diabetic Retinopathy Market and Pipeline by Therapeutic Target Family 34

5.3.2 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 35

5.3.3 Pipeline Products in Diabetic Complications 38

6 Signaling Network, Disease Causation and Innovation Alignment 41

6.1 Complexity of Signaling Networks in Metabolic Disorders 41

6.2 First-in-Class Matrix Assessment 42

7 First-in-Class Target Evaluation 44

7.1 Pipeline Programs Targeting XXX 44

7.2 Pipeline Programs Targeting XXX 45

7.3 Pipeline Programs Targeting XXX 46

7.4 Pipeline Programs Targeting XXX 47

7.5 Pipeline Programs Targeting XXX 48

7.6 Pipeline Programs Targeting XXX 50

7.7 Pipeline Programs Targeting XXX 51

7.8 Pipeline Programs Targeting XXX 53

8 Deals and Strategic Consolidations 54

8.1 Industry-Wide First-in-Class Deals 54

8.2 Licensing Deals 55

8.2.1 Licensing Deals by Molecule Type 57

8.2.2 Licensing Deals by Molecular Target 57

8.3 Co-development Deals 59

8.3.1 Co-development Deals by Molecule Type 60

8.3.2 Co-development Deals by Molecular Target 60

8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 62

9 Appendix 66

9.1 References 66

9.2 Abbreviations 71

9.3 Research Methodology 71

9.4 Secondary Research 72

9.4.1 Market Analysis 72

9.4.2 Pipeline Analysis 72

9.4.3 First-in-Class Matrix Assessment 72

9.4.4 First-in-Class Target Profiles 73

9.4.5 Licensing and Co-Development Deals 73

9.5 Contact Us 73

9.6 Disclaimer 73

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards